Project title: Prophylactic treatment of Preeclampsia: Pharmacology and pharmacodynamics of placental protein 13 (PP13) and low-dose aspirin
About project: Preeclampsia (PE) is one of the major tasks in obstetrics, having unclear causes and diagnosed in the second and third trimester. It is characterized by high blood pressure and proteinurea in previously normotensive women. This disease often leads to preterm delivery, or before 34 – 35 weeks of gestation. Preeclampsia is a major cause of the perinatal and maternal mobidity and mortality and affects 2-8% of pregnancies worldwide. It is assumed that origins of the PE may be originated from the placenta and need to be detected in early first trimester. One of the main causes of the disease is believed to be unbalance between thromboxane and prostacyclin in spiral arteries and/or failure in trophoblast invasion. Recent studies have shown low concentration of placental protein 13 (eclampsin, PP13) in maternal blood in early pregnancy in women likely to develop PE. The focus of this project will be study the pharmacology of aspirin and PP13 as prophylactic agents to prevent the development of PE.
Supervisor: Sveinbjörn Gizurarson
M.Sc. in Pharmacy 2013 at UI. The project was carried out in collaboration with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany.